NORMAN DAMRON: Open Payments
NPI 1275034845 · NEWBURGH, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$870 in 39 payments from 21 companies in 2025. Trend: 2023 $250 · 2024 $299 · 2025 $870
Food & beverage: $870
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 5 | $113 |
| Janssen Biotech, Inc. | 5 | $94 |
| Merck Sharp & Dohme LLC | 5 | $84 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $69 |
| Syndax Pharmaceuticals, Inc. | 2 | $57 |
| Daiichi Sankyo Inc. | 2 | $54 |
| ABBVIE INC. | 2 | $46 |
| Blueprint Medicines Corporation | 1 | $37 |
| Geron Corporation | 1 | $32 |
| Genmab U.S., Inc. | 1 | $30 |
Products named: KISQALI, KEYTRUDA, CARVYKTI, AYVAKIT, RYTELO, RYBREVANT, Epkinly, Orserdu.
Industry payments across IN — which companies pay providers there.
